Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.

van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA.

J Urol. 2006 Oct;176(4 Pt 1):1349-53; discussion 1353.

PMID:
16952629
2.

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

Puri R, Palit V, Loadman PM, Flannigan M, Shah T, Choudry GA, Basu S, Double JA, Lenaz G, Chawla S, Beer M, Van Kalken C, de Boer R, Beijnen JH, Twelves CJ, Phillips RM.

J Urol. 2006 Oct;176(4 Pt 1):1344-8.

PMID:
16952628
3.

Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.

Hendricksen K, Gleason D, Young JM, Saltzstein D, Gershman A, Lerner S, Witjes JA.

J Urol. 2008 Jul;180(1):116-20. doi: 10.1016/j.juro.2008.03.031. Epub 2008 May 15.

PMID:
18485407
4.

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer.

Hendricksen K, van der Heijden AG, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Smits GA, Puri R, Gruijs S, Witjes JA.

World J Urol. 2009 Jun;27(3):337-42. doi: 10.1007/s00345-009-0382-4. Epub 2009 Feb 13.

5.

The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.

Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, Sylvester R; European Organization for Research and Treatment of Cancer Genitourinary Group.

J Urol. 2001 Feb;165(2):401-3.

PMID:
11176382
6.

Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer.

Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla S, Witjes JA.

J Urol. 2012 Apr;187(4):1195-9. doi: 10.1016/j.juro.2011.11.101. Epub 2012 Feb 14.

PMID:
22335860
7.

Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.

Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, Puri R.

Urology. 2009 May;73(5):1083-6. doi: 10.1016/j.urology.2007.12.062. Epub 2009 Feb 20.

PMID:
19232688
9.

A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.

Uchio EM, Linehan WM, Figg WD, Walther MM.

J Urol. 2003 Jan;169(1):357-60.

PMID:
12478189
10.

Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin.

Popert RJ, Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR.

Br J Urol. 1994 Aug;74(2):195-9.

PMID:
7921938
11.

Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group.

Bono AV, Hall RR, Denis L, Lovisolo JA, Sylvester R.

Eur Urol. 1996;29(4):385-90.

PMID:
8791042
12.

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.

Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA.

Eur Urol. 2008 May;53(5):984-91. doi: 10.1016/j.eururo.2007.12.033. Epub 2007 Dec 27.

PMID:
18248876
13.

Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.

Oosterlinck W, Bono AV, Mack D, Hall R, Sylvester R, de Balincourt C, Brausi M; Members of the EORTC GU Group.

Eur Urol. 2001 Nov;40(5):515-7.

PMID:
11752858
16.

Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.

Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y.

Urology. 2007 Feb;69(2):275-9.

PMID:
17320663
17.

Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).

de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P; European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.

J Urol. 2005 Feb;173(2):405-9.

PMID:
15643181
18.

Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract.

Elsässer-Beile U, Leiber C, Wolf P, Lucht M, Mengs U, Wetterauer U.

J Urol. 2005 Jul;174(1):76-9.

PMID:
15947582
19.

Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.

Whelan P, Cumming JA, Garvie WH, Hargreave TB, Kirk D, Newling DW, Robinson MR, Smith PH.

Br J Urol. 1991 Jun;67(6):600-2.

PMID:
2070204
20.

Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study.

Namasivayam S, Whelan P.

Br J Urol. 1995 Jun;75(6):740-3.

PMID:
7613831

Supplemental Content

Support Center